Samsung Bioepis and Organon announced that the FDA has accepted for review the supplemental biologics license application, or sBLA, for the interchangeability designation for Hadlima injection 40 mg/0.4 mL, a biosimilar to Humira. The sBLA was submitted to the FDA by Samsung Bioepis in August 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OGN:
- Organon and Co call volume above normal and directionally bullish
- Organon price target lowered to $25 from $28 at Barclays
- Ex-Dividend Date Nearing for These 10 Stocks – Week of November 6-10, 2023
- Goldman downgrades Organon to Neutral on ‘agglomeration of issues’
- Organon downgraded to Neutral from Buy at Goldman Sachs
